<li id="omoqo"></li>
  • <noscript id="omoqo"><kbd id="omoqo"></kbd></noscript>
  • <td id="omoqo"></td>
  • <option id="omoqo"><noscript id="omoqo"></noscript></option>
  • <noscript id="omoqo"><source id="omoqo"></source></noscript>
  • 發布時間:2019-08-03 21:35 原文鏈接: TranscriptionalactivationofdbpbfrommRNA

    Endothelial cells respond to treatment with the protease thrombin with increased secretion of the PDGF B-chain. This activation occurs at the transcriptional level and a thrombin response element was identified in the promoter of the PDGF B-chain gene. A transcription factor called the DNA-binding protein B (dbpB) mediates the activation of PDGF B-chain transcription in response to thrombin treatment. DbpB is a member of the Y box family of transcription factors and binds to both RNA and DNA. In the absence of thrombin, endothelial cells contain a 50 kD form of dbpB that binds RNA in the cytoplasm and may play a role as a chaperone for mRNA. The 50 kD version of dbpB also binds DNA to regulate genes containing Y box elements in their promoters. Thrombin activation results in the cleavage of dbpB to a 30 kD form. The proteolytic cleavage releases dbpB from RNA in the nucleus, allowing it to enter the nucleus and binds to a regulatory element distinct from the site recognized by the full length 50 kD dbpB. The genes activated by cleaved dbpB include the PDGF B chain. Dephosphorylation of dbpB also regulates nuclear entry and transcriptional activation. RNA digestion in vitro can release dbpB in its active form, suggesting that the protease responsible for dbpB may be closely associated in a complex. Identification of the protease that cleaves dbpB, the mechanisms of phosphorylation and dephosphorylation, and elucidation of the signaling path by which thrombin induces dbpB will provide greater understanding of this novel signaling pathway.

    Contributor:

    REFERENCES: Olga Stenina, Kristn Shanneyfelt and Paul Dicorleto. Thrombin induces the release of the Y-box protein dbpB from mRNA: A mechanism of transcriptional activation. PNAS 98:7277-7282 (2001)


    相關文章

    復星醫藥宣布啟動新冠疫苗國內二期臨床

    11月25日,復星醫藥和德國BioNTech共同宣布,其首選mRNA候選新冠疫苗BNT162b2將在中國江蘇泰州和漣水開展II期臨床試驗。值得一提的是,該款疫苗在海外Ⅲ期臨床結果顯示,其有效性達到驚人......

    郭廣昌:這款mRNA新冠疫苗有效率高達90%

    郭廣昌在個人微信公眾號發文稱,復星新冠疫苗在全球的研發合作伙伴輝瑞和BioNTech剛剛宣布,根據三期臨床試驗的初步分析數據,這次我們合作研發的mRNA疫苗有效率高達90%,而普通流感疫苗也只有70%......

    生物物理所揭示皰疹病毒抑制宿主mRNA機制

    病毒在與宿主長期的博弈過程中,進化出多種機制來對抗和逃避宿主的抗病毒反應。其中,通過干預宿主的mRNA出核轉運過程,進而阻止宿主細胞建立合適的抗病毒環境,是重要策略之一。例如,甲型流感病毒NS1蛋白和......

    我國研究揭示鋅指抗病毒蛋白ZAP識別RNA的分子機制

    鋅指抗病毒蛋白(Zinc-fingerAntiviralprotein,ZAP)是一種由宿主編碼的重要抗病毒因子,ZAP特異能夠抑制包括小鼠白血病病毒、艾滋病病毒、埃博拉病毒等在內的多種病毒復制。ZA......

    新冠疫苗研發賽道競速!mRNA技術大熱

    當前海外新冠疫情形勢嚴峻,累計確診病例已超過中國。新冠肺炎在全球范圍內蔓延,疫苗作為控制和預防病毒的有效手段之一,研發的重要性進一步凸顯。多家藥企入局,mRNA技術備受矚目據美聯社報道,一項針對新型冠......

    簡述寡聚(dT)纖維素柱層析法提取mRNA的原理

    真核細胞的mRNA分子最顯著的結構特征是具有5’端帽子結構(m7G)和3’端的Poly(A)尾巴。絕大多數哺乳類動物細胞mRNA的3’端存在20-30個腺苷酸組成的Poly(A)尾,通常用Poly(A......

    Moderna交付首批新冠病毒疫苗將用于人體臨床試驗

    據24日媒體報道,Moderna歷時一個月攻堅,已快速開發出了應用于新冠肺炎的疫苗,并運送到了美國國家過敏和傳染病研究所(NIAID),計劃在四月底之前,對20-25名健康志愿者進行藥物測試,意味著火......

    Science:神經元突起中,單核糖體偏好性地翻譯突觸mRNA

    RNA測序和原位雜交揭示了神經元樹突和軸突中存在意想不到的大量RNA種類,而且許多研究已經記錄了蛋白在這些區室中的局部翻譯。在信使RNA(mRNA)的翻譯過程中,多個核糖體可以同時占據單個mRNA(一......

    一文讀懂21世紀的新型疫苗技術

    疫苗開發的新方法包括基于結構的免疫原設計,基于基因的疫苗平臺以及具有有效佐劑的重組抗原制劑。這些技術在開發針對全球重要疾病(例如結核病,流感和呼吸道合胞病毒)的疫苗方面取得令人鼓舞的結果。在這里,我們......

    研究揭示LARP7在生精細胞mRNA精準剪接和精子發生中的功能

    2月3日,國際學術期刊MolecularCell在線發表了中國科學院分子細胞科學卓越創新中心/生物化學與細胞生物學研究所劉默芳研究組的最新研究成果“LARP7-MediatedU6snRNAModif......

    <li id="omoqo"></li>
  • <noscript id="omoqo"><kbd id="omoqo"></kbd></noscript>
  • <td id="omoqo"></td>
  • <option id="omoqo"><noscript id="omoqo"></noscript></option>
  • <noscript id="omoqo"><source id="omoqo"></source></noscript>
  • 1v3多肉多车高校生活的玩视频